VERAXA Biotech AG (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, who previously served as vice president of research and development, will lead the advancement of the company’s proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period.
Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the company’s oncology pipeline and advance BiTAC(R) candidates toward clinical development.
The appointment comes at a critical juncture for VERAXA as it seeks to move its pipeline of bispecific T cell engagers and antibody-drug conjugates (ADCs) into clinical trials. The BiTAC platform, which is designed to harness the immune system to target and destroy cancer cells, represents a key strategic asset for the company. According to the press release, VERAXA is building “a premier engine for the discovery and development of next-generation antibody-based therapeutics.”
Erkel’s background in leading immuno-oncology programs at MorphoSys, a company known for its antibody discovery and development capabilities, is expected to accelerate VERAXA’s progress. The company’s technology originated from scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), a world-renowned research institution.
The news is significant for investors and the biotech sector as it signals VERAXA’s commitment to advancing its solid tumor pipeline. Solid tumors represent a large and challenging area in oncology, and successful development of BiTAC-based therapies could address significant unmet medical needs. The appointment also provides continuity in scientific leadership, as Erkel was already familiar with the company’s research programs from his previous role.
For more details, the full press release is available at https://nnw.fm/cR1RS. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
